Abstract
Patients of minority race with myeloma have had less increase in population-level survival in the early 21st century than white patients.
Data from clinical trials show that mortality is similar for minorities, suggesting the population-level difference is due to utilization.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Clinical Trials as Topic
-
Ethnicity
-
Female
-
Humans
-
Immunologic Factors / therapeutic use
-
Immunomodulation / drug effects
-
Male
-
Middle Aged
-
Minority Groups
-
Multiple Myeloma / drug therapy
-
Multiple Myeloma / epidemiology
-
Multiple Myeloma / ethnology
-
Multiple Myeloma / mortality*
-
Proteasome Inhibitors / therapeutic use
Substances
-
Immunologic Factors
-
Proteasome Inhibitors